Vir Biotechnology, Inc. (VIR) Financial Statements
Vir Biotechnology, Inc. (VIR) reported trailing twelve-month revenue of $303.2M (up 1495.9% year on year) and net income of -$251.7M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$203.6M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
VIRVir Biotechnology, Inc.Follow VIR — free
—
Price chart with a free account
- Market cap
- 1.8B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.01 | 0.08 | 1.10 | 1.62 | 0.09 | 0.07 | 0.07 | 0.30 | |
| Gross profit | — | — | 1.03 | 1.47 | 0.08 | 0.07 | 0.07 | — | |
| Research & development | 0.15 | 0.30 | 0.45 | 0.47 | 0.58 | 0.51 | 0.46 | 0.48 | |
| Operating income | -0.18 | -0.30 | 0.42 | 0.83 | -0.68 | -0.59 | -0.48 | -0.28 | |
| Pre-tax income | -0.17 | -0.30 | 0.55 | 0.75 | -0.63 | -0.52 | -0.44 | -0.25 | |
| Income tax | 0.00 | 0.00 | 0.02 | 0.24 | -0.01 | -0.00 | 0.00 | 0.00 | |
| Net income | -0.17 | -0.30 | 0.53 | 0.52 | -0.62 | -0.52 | -0.44 | -0.25 | |
| Diluted EPS ($) | -5.76 | -2.51 | 3.96 | 3.83 | -4.59 | -3.83 | -3.16 | -1.48 | |
| Diluted shares (bn) | — | — | 0.133 | 0.135 | 0.134 | 0.136 | 0.139 | — |
USD billions · SEC XBRL
Vir Biotechnology, Inc. — questions
- What is Vir Biotechnology, Inc.'s revenue?
- $303.2M over the twelve months to 2026-06-30, up 1495.9% year on year, from its 10-Q and 10-K filings.
- What is Vir Biotechnology, Inc.'s net income?
- -$251.7M over the twelve months to 2026-06-30.
- What is Vir Biotechnology, Inc.'s free cash flow?
- -$203.6M over the twelve months to 2026-06-30.
- What are Vir Biotechnology, Inc.'s diluted earnings per share?
- $-1.48 over the twelve months to 2026-06-30.
Every figure on this page comes from Vir Biotechnology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.